Nicholas Robert
Overview
Explore the profile of Nicholas Robert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Walker B, Kavadi V, Wilfong L, Robert N
Am J Manag Care
. 2022 Oct;
28(10):515-519.
PMID: 36252170
Objectives: CMS created the Oncology Care Model (OCM) to increase the delivery of cost-efficient cancer care, but in linking medical oncologist compensation to total costs of care, the model also...
12.
Merola D, Young J, Schrag D, Lin K, Robert N, Schneeweiss S
Clin Epidemiol
. 2022 Oct;
14:1135-1144.
PMID: 36246306
Background: The use of electronic health records (EHR) data to assess drug effectiveness in clinical oncology practice is of great interest to regulators, clinicians, and payers. However, the utility of...
13.
Webster-Clark M, Keil A, Robert N, Frytak J, Boyd M, Sturmer T, et al.
JAMA Oncol
. 2022 Oct;
PMID: 36227604
Importance: Delivery of adjuvant chemotherapy can differ substantially between trial and real-world populations. Adherence metrics like relative dose intensity (RDI) cannot capture the timing of modifications and mask differences in...
14.
Walker B, Wilfong L, Frytak J, Robert N
J Cancer Policy
. 2022 May;
29:100294.
PMID: 35559949
Background: The Oncology Care Model (OCM) incentivized care coordination and cost-efficiency and has been associated with short-term care reductions, but its multi-year associations are less well-studied. Methods: We used monthly...
15.
Annavarapu S, Gogate A, Pham T, Davies K, Singh P, Robert N
CNS Oncol
. 2021 Aug;
10(3):CNS76.
PMID: 34378977
Investigate real-world outcomes and healthcare utilization of patients with glioblastoma multiforme (GBM) related to O-methylguanine DNA methyltransferase (MGMT) promoter testing and methylation. US Oncology Network data were analyzed for patients...
16.
OShaughnessy J, Robert N, Annavarapu S, Zhou J, Sussell J, Cheng A, et al.
Breast Cancer Res Treat
. 2021 Mar;
187(3):903-913.
PMID: 33649981
Purpose: This study assessed real-world risk of invasive disease recurrence (IDR) and associated factors in patients with human epidermal growth factor receptor-2 positive (HER2+) early breast cancer (BC) with pathological...
17.
Walker B, Boyd M, Aguilar K, Davies K, Espirito J, Frytak J, et al.
JCO Clin Cancer Inform
. 2021 Jan;
5:45-46.
PMID: 33411622
No abstract available.
18.
Walker B, Frytak J, Hayes J, Neubauer M, Robert N, Wilfong L
JAMA Netw Open
. 2020 May;
3(5):e205165.
PMID: 32421185
Importance: Health insurers reimburse clinicians in many ways, including the ubiquitous fee-for-service model and the emergent shared-savings models. Evidence on the effects of these emergent models in oncological treatment remains...
19.
Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat A
Future Oncol
. 2019 Apr;
15(12):1323-1334.
PMID: 30942088
Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC). Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community...
20.
Seeber A, Chahine G, Nasr F, Dean A, Miranova M, Jameson G, et al.
Cancer J
. 2019 Mar;
25(2):73-79.
PMID: 30896526
Purpose: Improvements in systemic treatment have led to a prolongation of survival and quality of life in patients with metastatic tumors in recent years. However, despite this improved standard of...